Blood cancer patients get chance to continue promising treatment

NCT ID NCT06465433

Recruiting now Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

Summary

This study allows patients with blood cancers who are already benefiting from tafasitamab treatment in a previous trial to continue receiving it. It aims to monitor the safety of this extended therapy for up to 25 participants. The study is specifically for patients whose disease is responding well to the current treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinica Universitad de Navarra
COMPLETED

Pamplona, 31008, Spain
Gazi University Hospital Gazi University Faculty of Medicine
RECRUITING

Ankara, 06500, Turkey (Türkiye)
Hospital S.M. Terni University of Perugia
COMPLETED

Terni, 05100, Italy
Petz Aladar County Teaching Hospital
RECRUITING

Győr, 09023, Hungary
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea

Conditions

Explore the condition pages connected to this study.

HEMATOLOGIC MALIGNANCIES